MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)。

Vorinostat

CAS No. : 149647-78-9

MCE 國(guó)際站：Vorinostat

產(chǎn)品活性：Vorinostat (SAHA) 是一種有效的，可口服的 HDAC1，HDAC2，HDAC3 (Class I)，HDAC6 和 HDAC7 (Class II) 和 Class IV (HDAC11) 的抑制劑，對(duì) HDAC1/3 的 ID₅₀ 值分別為 10 nM 和 20 nM。Vorinostat 可以誘導(dǎo)細(xì)胞凋亡 (apoptosis)。Vorinostat 還是一種人類乳頭瘤病毒 (HPV)-18 DNA 擴(kuò)增的有效抑制劑。

研究領(lǐng)域：Cell Cycle/DNA Damage  |  Epigenetics  |  Autophagy  |  Anti-infection  |  Apoptosis

作用靶點(diǎn)：HDAC  |  Autophagy  |  Mitophagy  |  Filovirus  |  Apoptosis  |  HPV

In Vitro: Vorinostat efficiently suppresses MES-SA cell growth at a low dosage (3 μM) already after 24 hours treatment. HDACs class I (HDAC2 and 3) as well as class II (HDAC7) are preferentially affected by this treatment. Vorinostat significantly increases p21^WAF1 expression and apoptosis in MES-SA cells.
Vorinostat inhibits SK-N-SH and SK-N-Be(2)C with the IC₂₅ values of 1 µM and 0.5 µM, respectively.
Vorinostat is an effective inhibitor of HPV-18 DNA amplification, reduces oncoproteins E6 and E7 activities and triggers apoptosis in HPV-infected, differentiated cells.

In Vivo: Vorinostat (50 mg/kg/day) reduces tumor growth by more than 50% in nude mice injected with 5×10⁶ MES-SA cells.

相關(guān)產(chǎn)品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Apoptosis Compound Library  |  Cell Cycle/DNA Damage Compound Library  |  Epigenetics Compound Library  |  FDA-Approved Drug Library  |  Histone Modification Research Compound Library  |  Anti-Cancer Compound Library  |  Antiviral Compound Library  |  CNS-Penetrant Compound Library  |  Autophagy Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Reprogramming Compound Library  |  Oxygen Sensing Compound Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Anti-Breast Cancer Compound Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Targeted Therapy Drug Library   |  Mitochondria-Targeted Compound Library  |  Anti-Liver Cancer Compound Library   |  Rare Diseases Drug Library  |  Children’s Drug Library  |  FDA-Approved Anticancer Drug Library  |  Human Metabolite Library  |  Anti-Prostate Cancer Compound Library  |  Anti-Pulmonary Fibrosis Compound Library  |  Osteogenesis Compound Library  |  Withdrawn Drug Compound Library  |  Mitochondrial Protection Compound Library  |  Cell Death Library  |  MG-132  |  3-Methyladenine  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  Olaparib  |  LY294002  |  Tamoxifen  |  Paclitaxel  |  Y-27632  |  Dexamethasone  |  Acetylcysteine  |  Angiotensin II human  |  2-Deoxy-D-glucose  |  Staurosporine  |  SB-431542  |  Actinomycin D  |  Deferoxamine mesylate  |  Bortezomib  |  5-Fluorouracil  |  Trametinib  |  Sorafenib  |  Oxaliplatin  |  Gemcitabine  |  Temozolomide  |  Adezmapimod  |  Rotenone  |  Mdivi-1  |  Elesclomol  |  Ruxolitinib  |  Decitabine

熱門產(chǎn)品線：重組蛋白  |  化合物庫(kù)  |  天然產(chǎn)物  |  熒光染料  |  PROTAC  |  同位素標(biāo)記物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds